Abstract
The purpose of the study is to review the efficacy of target-specific oral anticoagulants (TSOAC) vs vitamin K antagonist for postsurgical anticoagulation in patients with primary subclavian vein thrombosis. Rivaroxaban and apixaban are newer TSOAC used in deep venous thrombosis (DVT) treatment and prophylaxis. However, the efficacy and safety of TSOAC for the prevention of recurrent deep vein thrombosis after revascularization of upper extremity compression syndromes is largely unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
